Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $185.8 million.

  • Enanta Pharmaceuticals' Cash & Current Investments fell 1423.32% to $185.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $185.8 million, marking a year-over-year decrease of 1423.32%. This contributed to the annual value of $188.9 million for FY2025, which is 2390.22% down from last year.
  • Per Enanta Pharmaceuticals' latest filing, its Cash & Current Investments stood at $185.8 million for Q4 2025, which was down 1423.32% from $188.9 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Cash & Current Investments' 5-year high stood at $386.6 million during Q2 2023, with a 5-year trough of $185.8 million in Q4 2025.
  • Its 5-year average for Cash & Current Investments is $260.2 million, with a median of $248.7 million in 2022.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first soared by 5720.19% in 2023, then plummeted by 4048.27% in 2024.
  • Quarter analysis of 5 years shows Enanta Pharmaceuticals' Cash & Current Investments stood at $259.1 million in 2021, then fell by 17.21% to $214.5 million in 2022, then soared by 57.2% to $337.2 million in 2023, then tumbled by 35.73% to $216.7 million in 2024, then fell by 14.23% to $185.8 million in 2025.
  • Its Cash & Current Investments stands at $185.8 million for Q4 2025, versus $188.9 million for Q3 2025 and $204.1 million for Q2 2025.